Defunct Company
Total Trials
24
As Lead Sponsor
21
As Collaborator
3
Total Enrollment
7,456
NCT00080236
Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation
Phase: Phase 2
Role: Lead Sponsor
Start: Nov 30, 2003
Completion: Jan 31, 2006
NCT00088140
A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients
Start: Jul 31, 2004
Completion: Oct 31, 2005
NCT00620802
Pharmacodynamics of CGT 2168 Compared With Plavix®
Phase: Phase 1
Start: Nov 30, 2007
Completion: May 31, 2008
NCT00557921
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
Phase: Phase 3
Start: Dec 31, 2007
Completion: Nov 30, 2009
NCT00570336
Study of CTS-1027 in Hepatitis C Patients
Completion: Jul 31, 2009
NCT00925990
CTS-1027 in Interferon-Naive Hepatitis C Patients
Start: Jun 30, 2009
Completion: Jul 31, 2010
NCT01051921
Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders
Start: Jan 31, 2010
Completion: Dec 31, 2011
NCT01273064
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
Start: Jan 31, 2011
Completion: Oct 31, 2011
NCT01653899
Caspase Inhibition in Islet Transplantation
Phase: Phase 1/2
Role: Collaborator
Start: Jun 30, 2012
Completion: Jun 30, 2016
NCT01912404
Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy
Start: Jul 31, 2013
Completion: Aug 31, 2015
NCT01937130
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
Start: Sep 30, 2013
Completion: Feb 28, 2015
NCT02039817
PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers
Start: Jan 31, 2014
Completion: Apr 30, 2014
NCT02077374
A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
Start: Mar 31, 2014
Completion: Mar 31, 2015
NCT02121860
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
Start: Apr 30, 2014
Completion: Jul 31, 2014
NCT02138253
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
Start: May 31, 2014
Completion: Mar 9, 2018
NCT02230670
A Study of IDN-6556 in Subjects With Liver Cirrhosis
Start: Aug 31, 2014
Completion: Jan 31, 2016
NCT02230683
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension
Completion: Jun 30, 2015
NCT02686762
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
Start: Jan 26, 2016
Completion: Feb 28, 2019
NCT03439189
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14
Phase: N/A
Start: Aug 28, 2016
Completion: May 13, 2019
NCT03205345
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
Start: Jun 28, 2017
Completion: Aug 31, 2019
NCT03462576
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17
Completion: Jul 15, 2019
NCT03479125
Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo
Start: Feb 27, 2018
Completion: Sep 30, 2019
NCT06614751
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
Start: Nov 1, 2024
Completion: Jun 1, 2027
NCT06998173
Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor
Start: Jul 31, 2025
Completion: Jul 30, 2028